Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
Novel agents, including Bruton tyrosine kinase inhibitors (BTKis), have become the standard of care for patients with chronic lymphocytic leukemia (CLL). We conducted a real-world retrospective analysis of patients with CLL treated with acalabrutinib vs ibrutinib using the Flatiron Health database. Patients with CLL were included if they initiated acalabrutinib or ibrutinib between 1 January 2018 and 28 February 2021. The primary outcome of interest was time to treatment discontinuation (TTD). Kaplan-Meier analysis was used to estimate unweighted and weighted median TTD. A weighted Cox proportional hazards model was used to compare the TTD between cohorts. Of the 2509 patients included in the analysis, 89.6% received ibrutinib, and 14.1% received acalabrutinib. TTD was not significantly different between cohorts in the unweighted analysis. After weighting, the cohorts were balanced on all baseline characteristics except cardiovascular risk factors and baseline medications use. The median (95% confidence interval [CI]) TTD was not reached (NR; 95% CI, 25.1 to NR) for the acalabrutinib cohort and was 23.4 months (95% CI, 18.1-28.7) for the ibrutinib cohort. The discontinuation rate at 12 months was 22% for the weighted acalabrutinib cohort vs 31% for the weighted ibrutinib cohort (P = .005). After additional adjustment for prior BTKi use, the acalabrutinib cohort had a 41% lower risk of discontinuation vs ibrutinib (hazard ratio, 0.59; 95% CI, 0.43-0.81; P = .001). In the largest available study comparing BTKis, patients with CLL receiving acalabrutinib demonstrated lower rates of discontinuation and a prolonged time to discontinuation vs those receiving ibrutinib.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
---|---|
Enthalten in: |
Blood advances - 7(2023), 16 vom: 22. Aug., Seite 4291-4301 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Roeker, Lindsey E [VerfasserIn] |
---|
Links: |
---|
Themen: |
1X70OSD4VX |
---|
Anmerkungen: |
Date Completed 11.08.2023 Date Revised 23.11.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1182/bloodadvances.2023009739 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM356662829 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM356662829 | ||
003 | DE-627 | ||
005 | 20231226070934.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1182/bloodadvances.2023009739 |2 doi | |
028 | 5 | 2 | |a pubmed24n1188.xml |
035 | |a (DE-627)NLM356662829 | ||
035 | |a (NLM)37163361 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Roeker, Lindsey E |e verfasserin |4 aut | |
245 | 1 | 0 | |a Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.08.2023 | ||
500 | |a Date Revised 23.11.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
520 | |a Novel agents, including Bruton tyrosine kinase inhibitors (BTKis), have become the standard of care for patients with chronic lymphocytic leukemia (CLL). We conducted a real-world retrospective analysis of patients with CLL treated with acalabrutinib vs ibrutinib using the Flatiron Health database. Patients with CLL were included if they initiated acalabrutinib or ibrutinib between 1 January 2018 and 28 February 2021. The primary outcome of interest was time to treatment discontinuation (TTD). Kaplan-Meier analysis was used to estimate unweighted and weighted median TTD. A weighted Cox proportional hazards model was used to compare the TTD between cohorts. Of the 2509 patients included in the analysis, 89.6% received ibrutinib, and 14.1% received acalabrutinib. TTD was not significantly different between cohorts in the unweighted analysis. After weighting, the cohorts were balanced on all baseline characteristics except cardiovascular risk factors and baseline medications use. The median (95% confidence interval [CI]) TTD was not reached (NR; 95% CI, 25.1 to NR) for the acalabrutinib cohort and was 23.4 months (95% CI, 18.1-28.7) for the ibrutinib cohort. The discontinuation rate at 12 months was 22% for the weighted acalabrutinib cohort vs 31% for the weighted ibrutinib cohort (P = .005). After additional adjustment for prior BTKi use, the acalabrutinib cohort had a 41% lower risk of discontinuation vs ibrutinib (hazard ratio, 0.59; 95% CI, 0.43-0.81; P = .001). In the largest available study comparing BTKis, patients with CLL receiving acalabrutinib demonstrated lower rates of discontinuation and a prolonged time to discontinuation vs those receiving ibrutinib | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a ibrutinib |2 NLM | |
650 | 7 | |a 1X70OSD4VX |2 NLM | |
650 | 7 | |a acalabrutinib |2 NLM | |
650 | 7 | |a I42748ELQW |2 NLM | |
650 | 7 | |a Adenine |2 NLM | |
650 | 7 | |a JAC85A2161 |2 NLM | |
700 | 1 | |a DerSarkissian, Maral |e verfasserin |4 aut | |
700 | 1 | |a Ryan, Kellie |e verfasserin |4 aut | |
700 | 1 | |a Chen, Yan |e verfasserin |4 aut | |
700 | 1 | |a Duh, Mei Sheng |e verfasserin |4 aut | |
700 | 1 | |a Wahlstrom, Svea K |e verfasserin |4 aut | |
700 | 1 | |a Hakre, Shweta |e verfasserin |4 aut | |
700 | 1 | |a Yu, Louise |e verfasserin |4 aut | |
700 | 1 | |a Guo, Helen |e verfasserin |4 aut | |
700 | 1 | |a Mato, Anthony R |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 7(2023), 16 vom: 22. Aug., Seite 4291-4301 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
773 | 1 | 8 | |g volume:7 |g year:2023 |g number:16 |g day:22 |g month:08 |g pages:4291-4301 |
856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2023009739 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 7 |j 2023 |e 16 |b 22 |c 08 |h 4291-4301 |